Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multimodality Treatment Including Pre- and Postoperative Systemic Chemotherapy Plus Cetuximab, Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis Arising From Wild Type K-ras Colon Cancer: A Prospective Multicenter Phase II Study.

NCT01540344 is registered in ClinicalTrials.gov with University of Regensburg as lead sponsor.

NCT NCT01540344
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01540344 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multimodality Treatment Including Pre- and Postoperative Systemic Chemotherapy Plus Cetuximab, Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis Arising From Wild Type K-ras Colon Cancer: A Prospective Multicenter Phase II Study.
Lead sponsor
University of Regensburg
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2010
Completion date
October 31, 2017
Enrollment
26 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer metastatic, peritoneal carcinomatosis